Skip to main content
. 2023 Feb 21;15(5):1358. doi: 10.3390/cancers15051358

Table 3.

Anti-oncomiRs enhance chemosensitivity in patients with CRC or mCRC.

Family miRNAs Verified Targets in CRC or Other Cancers Sample Source Target for miRNA Ref.
miR-8 miR-8,
miR-141,
miR-200a/b/c, miR-429		 MiR-141-3p enhanced the cetuximab sensitivity of CRC cells Tumor tissue ZEB1-ZEB2 [94,95]
Expression of miR-200c and miR-141 was downregulated in oxaliplatin-resistant CRC cell lines. EGFR [96]
miR-27 miR-27a,
miR-27b-3p		 MiR-27b-3p sensitizes CRC cells to oxaliplatin in vitro and in vivo, and miR-27b-3p expression was positively correlated with disease-free survival time in patients with CRC. Tumor tissue ATG10 [102]
miR-29 miR-29a,
miR-29b,
miR-29c		 Circulating miR-20b, miR-29b, and miR-155 expression levels were significantly associated with progression-free survival (p < 0.05) and overall survival (p < 0.05). Serum No data [71]
miR-34 miR-34a/b/c/d MiR-34a enhanced chemosensitivity to 5-FU. Serum E2F3; SIRT1. [87]
miR148 miR-148a/b,
miR-152		 MiR-148a suppressed the expression of stem cell markers and increased chemosensitivity, cell invasion, and cell migration. Tumor tissue WNT10b and beta-catenin signaling pathway. [69]
MiR-148a decreased angiogenesis and increased CRC cell apoptosis by downregulating HIF-1α/VEGF and Mcl-1, and serum miR-148a levels have prognostic or predictive value in patients with mCRC receiving bevacizumab. [103]
miR-154 miR-154,
miR-323a,
miR-369-3p,
miR-377,
miR-381,
miR-382,
miR-409,
miR-410		 MiR-377-3p expression levels in CRC samples (especially those from patients with stage III/IV CRC) were significantly lower than those in normal mucosa tissues. Overexpression of miR-377-3p enhanced the chemosensitivity of CRC cells by inhibiting Wnt/beta-catenin signaling by directly targeting ZEB2 and XIAP, which are positive regulators of Wnt/β-catenin signaling. Tumor tissue ZEB2 and XIAP [97]
MiR-382 functions as a tumor suppressor and chemosensitizer in CRC. [100]
miR-155 miR-155 Circulating expression levels of miR-20b, miR-29b, and miR-155 were significantly associated with progression-free survival (p < 0.05) and overall survival (p < 0.05). Serum No data [71]
MiR-155 induced radioresistance by targeting FOXO3a. FOXO3a. [104]
miR-193 miR-193a/b MiR-193b-5p enhanced chemosensitivity to 5-FU. Tumor tissue HMGA2/MAPK pathway [98]
CRC tissues and adjacent noncancerous tissues were obtained from 67 patients who had undergone surgery. Upregulation of miR-193-5p, particularly in combination with 5-FU and oxaliplatin, reduced the expression levels of CXCR4. A miR-193a-5p mimic suppressed CXCR4-induced CRC cell proliferation. CXCR4. [99]
miR-218 miR-218-1/2 MiR-218 enhanced 5-FU cytotoxicity by suppressing thymidylate synthase and MiR-218 promoted apoptosis, inhibited cell proliferation, and caused cell cycle arrest Tumor tissue thymidylate synthase; BIRC5 [105]
miR-330 miR-330 MiR-330 inhibited CRC cell proliferation and enhanced CRC cell chemosensitivity to 5-FU Tumor tissue Hexokinase 2 Thymidylate synthase [30]
[106]
miR-375 miR-375-3p MiR-375 enhanced CRC cell chemosensitivity to 5-FU by directly targeting YAP1 and SP1. Tumor tissue YAP1 and SP1 [107]
MiR-375 enhanced CRC cell chemosensitivity to 5-FU by targeting thymidylate synthase. Tumor tissue thymidylate synthase [108]
miR-488 miR-488 MiR-488 mimics transfected into CRC cell lines induced decreases in glucose uptake and increases in oxaliplatin/5-FU chemosensistivity. Serum PFKFB3 [109]
miR-1207 miR-1207-5p Upregulation of miR-1207-5p inhibited bevacizumab resistance in CRC cells. Tumor tissue ABCC1. [110]
miR-1287 miR-1287-5p Lower miR-1287-5p expression levels upregulate the mRNA expression of Y-box binding protein 1 (YBX1) and protein levels of YBX1, thereby inducing CRC cell proliferation and migration. Tumor tissue YBX1 [111]
The multifunctional YBX1 is overexpressed and phosphorylated in CRC and is associated with cetuximab resistance. [112]
miR-1915 miR-1915 Exosomal delivery of miR-1915-3p can improve the chemosensitivity of oxaliplatin by suppressing the epithelial–mesenchymal transition. Plasma PFKFB3 and USP2 [101]